Adult T-cell Leukemia/Lymphoma Clinical Trial
Official title:
A Phase 2, Multicenter, Open-label, Single-arm Study of Valemetostat Tosylate (DS-3201b) in Patients With Relapsed or Refractory Adult T-cell Leukemia/Lymphoma
Verified date | February 2024 |
Source | Daiichi Sankyo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This Phase 2 study will be conducted to assess the efficacy and safety of valemetostat tosylate (DS-3201b) in participants with relapsed or refractory adult T-cell leukemia/lymphoma (r/r ATL).
Status | Active, not recruiting |
Enrollment | 25 |
Est. completion date | December 31, 2025 |
Est. primary completion date | April 24, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - Participants with relapsed or refractory adult T-cell leukemia/lymphoma (ATL) who have history of treatment with mogamulizumab or are mogamulizumab intolerant, contraindication after treatment with at least 1 medication regimen - Aged =20 years or older at the time of signing the informed consent - Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2 - At least 1 evaluable lesion - Participants who have defined laboratory criteria - Life expectancy = 3 months Exclusion Criteria: - A presence of central nervous system involvement at the time of screening tests - Have poorly controlled complication (eg. chronic congestive heart failure, unstable angina - = Grade 3 neuropathy - QT interval corrected using Fridericia's method (QTcF) >470 ms - Has an uncontrolled infection - Participants who use corticosteroids over 10 mg/day - Receipt of allogeneic hematopoietic stem cell transplantation - History of, or concurrent, malignant tumors |
Country | Name | City | State |
---|---|---|---|
Japan | National Cancer Center Hospital | Chuo Ku | Tokyo |
Japan | Kyushu University Hospital | Fukuoka-shi | Fukuoka |
Japan | National Hospital Organization Kyushu Cancer Center | Fukuoka-shi | Fukuoka |
Japan | Hamamatsu University Hospital | Hamamatsu-shi | Shizuoka |
Japan | Saitama Medical University International Medical Center | Hidaka-shi | Saitama |
Japan | Kagoshima University Hospital | Kagoshima-city | |
Japan | Imamura General Hospital | Kagoshima-shi | Kagoshima |
Japan | National Cancer Center Hospital East | Kashiwa-shi | Chiba |
Japan | Kumamoto University Hospital | Kumamoto-shi | Kumamoto |
Japan | IMSUT Hospital, The Institute of Medical Science, The University of Tokyo | Minato-Ku | Tokyo |
Japan | University of Miyazaki Hospital | Miyazaki-shi | Miyazaki |
Japan | Nagasaki University Hospital | Nagasaki-shi | |
Japan | Nagoya City University Hospital | Nagoya-shi | Aichi |
Japan | University of the Ryukyus Hospital | Nakagami-gun | Okinawa |
Japan | Kochi Medical School Hospital | Nankoku-shi | Kochi |
Japan | Okayama University Hospital | Okayama-shi | Okayama |
Japan | Osaka International Cancer Institute | Osaka-shi | Osaka |
Japan | Kindai University Hospital | Osakasayama-shi | Osaka |
Japan | Saga University Hospital | Saga-shi | Saga |
Japan | Hokkaido University Hospital | Sapporo-shi | Hokkaido |
Japan | Local Incorporated Administrative Agency Sasebo City General Hospital | Sasebo-shi | Nagasaki |
Japan | National University Corporation Tohoku University Tohoku University Hospital | Sendai-shi | Miyagi |
Japan | Osaka University Hospital | Suita-shi | Osaka |
Japan | Ehime University Hospital | Toon-shi | Ehime |
Lead Sponsor | Collaborator |
---|---|
Daiichi Sankyo Co., Ltd. |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall response rate (ORR) assessed by central evaluation organization | The percentage of participants who were assessed for best overall response, who achieved complete remission (CR), complete remission, unconfirmed (CRu) or partial remission (PR) by central evaluation organization. | Through the end of the study (within approximately 5 years) | |
Secondary | Overall response rate (ORR) assessed by investigator | The percentage of participants who were assessed for best overall response, who achieved CR, CRu, or PR by investigator. | Through the end of the study (within approximately 5 years) | |
Secondary | Best response per tumor lesions | Best response in target lesions (nodal or extranodal lesions), peripheral blood lesions, and skin lesions. | Through the end of the study (within approximately 5 years) | |
Secondary | Complete remission rate (CR rate) | The percentage of participants who were assessed for best overall response, who achieved CR or CRu. | Through the end of the study (within approximately 5 years) | |
Secondary | Tumor control rate (TCR) | The percentage of participants who were assessed for best overall response, who achieved CR, CRu, PR or stable disease (SD). | Through the end of the study (within approximately 5 years) | |
Secondary | Time to response (TTR) | Period from the first day of DS-3201b dose to the first day of CR, CRu, or PR | Through the end of the study (within approximately 5 years) | |
Secondary | Duration of response (DOR) | Period from first CR, CRu, or PR to residual disease/progressive disease (RD/PD) or death. | Through the end of the study (within approximately 5 years) | |
Secondary | Progression-free survival (PFS) | Period from the first day of DS-3201b dose to the day of RD/PD or death. | Through the end of the study (within approximately 5 years) | |
Secondary | Overall survival (OS) | Period from the first day of DS-3201b dose to death. | Through the end of the study (within approximately 5 years) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03264131 -
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
|
Phase 2 | |
Withdrawn |
NCT05321940 -
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
|
Phase 1 | |
Withdrawn |
NCT04639843 -
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT03113500 -
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
|
Phase 2 | |
Recruiting |
NCT02588651 -
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
|
Phase 2 | |
Recruiting |
NCT05978141 -
A Registry for People With T-cell Lymphoma
|
||
Completed |
NCT01184885 -
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
|
Early Phase 1 | |
Completed |
NCT02652715 -
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT02631746 -
Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
|
Phase 2 | |
Recruiting |
NCT04301076 -
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)
|
Phase 1 |